



Original Effective Date: 07/23/2020
Current Effective Date: 03/13/2026
Last P&T Approval/Version: 01/28/2026
Next Review Due By: 01/2027
Policy Number: C19330-A

Koselugo (selumetinib)

PRODUCTS AFFECTED

Koselugo (selumetinib)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

DIAGNOSIS:

Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN)

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review. When the requested drug product for coverage is dosed by weight, body surface area or other member specific measurement, this data element is required as part of the medical necessity review. The Pharmacy and Therapeutics Committee has determined that the drug benefit shall be a mandatory generic and that generic drugs will be dispensed whenever available.

Drug and Biologic Coverage Criteria

A. NEUROFIBROMATOSIS TYPE 1 PLEXIFORM NEUROFIBROMAS:

1. Documented diagnosis of Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN)
AND
2. Documentation member has at least one measurable PN, defined as a lesion ≥ 3 cm measured in one dimension
AND
3. Documentation that complete resection of PN is not considered to be feasible without substantial risk or morbidity (e.g., due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN)
AND
4. Documentation that member is symptomatic (i.e., experiencing pain, motor dysfunction, and visual loss)
AND
5. Prescriber attests to (or clinical reviewer has found that) the member not having any FDA labeled contraindications that haven't been addressed by the prescriber within the documentation submitted for review [Contraindications to Koselugo (selumetinib) include: avoid concomitant use of strong and moderate CYP3A4 inducers (e.g., butalbital, carbamazepine, rifampin, etc.), concomitant use of St. John's wort, pregnancy (including female partners of reproductive potential with male patients)]
AND
6. Documentation member's BSA is at least 0.55 m² for capsule requests OR Documentation member's BSA is at least 0.40 m² for oral granule requests

CONTINUATION OF THERAPY:

A. NEUROFIBROMATOSIS TYPE 1 PLEXIFORM NEUROFIBROMAS:

1. Adherence to therapy at least 85% of the time as verified by Prescriber and member's medication fill history (review Rx history for compliance) unless therapy held for toxicity
AND
2. Documentation of positive clinical response as demonstrated by no evidence of disease progression or unacceptable toxicity (See Appendix)

DURATION OF APPROVAL:

Initial authorization: 12 months, Continuation of Therapy: 12 months

PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with an oncologist or a neurologist [If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests]

AGE RESTRICTIONS:

1 year of age and older

QUANTITY:

25mg/m² twice a day - See charts

Recommended dosage for Koselugo capsules

Body Surface Area*	Recommended Dosage
0.55 – 0.69 m ²	20 mg in the morning and 10 mg in the evening
0.70 – 0.89 m ²	20 mg twice daily

Drug and Biologic Coverage Criteria

0.90 – 1.09 m2	25 mg twice daily
1.10 – 1.29 m2	30 mg twice daily
1.30 – 1.49 m2	35 mg twice daily
1.50 – 1.69 m2	40 mg twice daily
1.70 – 1.89 m2	45 mg twice daily
≥ 1.90 m2	50 mg twice daily

Maximum Quantity Limits – Minimum quantity of both strengths necessary to make dose

Recommended dosage for Koselugo oral granules

Body Surface Area*	Recommended Dosage
0.40 – 0.59 m2	12.5 mg twice daily
0.60 – 0.69 m2	15 mg twice daily
0.70 – 0.89 m2	20 mg twice daily
0.90 – 1.09 m2	25 mg twice daily
1.10 – 1.29 m2	30 mg twice daily
1.30 – 1.49 m2	35 mg twice daily
1.50 – 1.69 m2	40 mg twice daily
1.70 – 1.89 m2	45 mg twice daily
≥ 1.90 m2	50 mg twice daily

Maximum Quantity Limits – Minimum quantity of both strengths necessary to make dose

PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Oral

DRUG CLASS:

Antineoplastic - MEK Inhibitors

FDA-APPROVED USES:

Indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

COMPENDIAL APPROVED OFF-LABELED USES:

Recurrent or Progressive Circumscribed Glioma (NCCN Central Nervous System Cancers Circumscribed Glioma: Systemic Therapy Options GLIO-A 1 of 10), Primary Spinal Cord Tumors (NCCN Central Nervous System Cancers Primary Spinal Cord Tumors: Systemic Therapy PSCT-A)

APPENDIX

APPENDIX:

Adverse Reactions requiring permanent discontinuation of Koselugo:

- Cardiomyopathy: Symptomatic decreased left ventricular ejection fraction (LVEF)
- Cardiomyopathy: Grade 3 or 4 decreased LVEF
- Ocular Toxicity: Retinal vein occlusion (RVO)
- Gastrointestinal Toxicity: Grade 3 diarrhea that does not improve within 3 days, Grade 4 diarrhea
- Gastrointestinal Toxicity: Grade 3 or 4 colitis
- Increased Creatine Phosphokinase (CPK): Grade 4 increased CPK or any increased CPK and myalgia that does not improve within 3 weeks
- Increased Creatine Phosphokinase (CPK): Rhabdomyolysis

Monitor for severe skin rashes. Withhold, reduce dose, or permanently discontinue Koselugo based on severity of adverse reaction.

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

Neurofibromatosis type 1 (NF1) is a rare, progressive condition caused by a mutation or flaw in the NF1 gene. It occurs in approximately 1 out of 2,600–3,000 infants. About 50% of cases are due to an inherited autosomal dominant genetic disorder, while the other 50% of cases are due to sporadic genetic mutations. Plexiform neurofibromas (PN) are tumors involving the nerve sheaths which can grow anywhere in the body, including the face, extremities, areas around the spine and deep in the body where they may affect organs. NF1 is usually diagnosed in early childhood. It is characterized by changes in skin pigmentation, neurologic and skeletal impairments, and risk for development of benign and malignant tumors throughout life. The risk of developing a cancer is estimated to be about 7%.

Between 30% and 50% of patients born with NF1 develop one or more PNs. An Italian study by Maria Masocco in the Orphanet Journal of Rare Diseases (2011) noted the mean age for NF1-associated death was approximately 20 years lower than that for the general population.

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Koselugo (selumetinib) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to Koselugo (selumetinib) include: avoid concomitant use of strong and moderate CYP3A4 inducers, concomitant use of St. John's wort, pregnancy (including female partners of reproductive potential with male patients).

Exclusions/Discontinuation:

Assess ejection fraction prior to initiating treatment, every 3 months during the first year, then every 6 months thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue Koselugo based on severity of adverse reaction.

Conduct ophthalmic assessments prior to initiating Koselugo, at regular intervals during treatment and for new or worsening visual changes. Permanently discontinue Koselugo for retinal vein occlusion (RVO).

Advise patients to start an anti-diarrheal agent immediately after the first episode of loose stool and to increase fluid intake. Withhold, reduce the dose, or permanently discontinue Koselugo based on severity of adverse reaction.

Monitor for severe skin rashes. Withhold, reduce the dose, or permanently discontinue

Drug and Biologic Coverage Criteria

Koselugo based on severity of adverse reaction.

Increased creatine phosphokinase (CPK) and rhabdomyolysis can occur. Obtain serum CPK prior to initiating Koselugo, periodically during treatment, and as clinically indicated. If increased CPK occurs, evaluate for rhabdomyolysis or other causes. Withhold, reduce the dose, or permanently discontinue Koselugo based on severity of adverse reaction.

Advise women not to breastfeed during treatment with Koselugo and for 1 week after the last dose due to the potential for adverse reactions in a breastfed child.

OTHER SPECIAL CONSIDERATIONS:

Verify the pregnancy status of females of reproductive potential prior to initiating Koselugo. Advise females of reproductive potential to use effective contraception during treatment and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Koselugo and for 1 week after the last dose.

Koselugo capsules contain vitamin E (10 mg capsules contain 32 mg vitamin E as the excipient, D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS); while Koselugo 25 mg capsules contain 36 mg vitamin E as TPGS). Vitamin E can inhibit platelet aggregation and antagonize vitamin K-dependent clotting factors. Daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in Koselugo and supplement) will exceed the recommended or safe limits.

CODING/BILLING INFORMATION

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive or applicable for every state or line of business. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry-standard coding practices for all submissions. Molina has the right to reject/deny the claim and recover claim payment(s) if it is determined it is not billed appropriately or not a covered benefit. Molina reserves the right to revise this policy as needed.

HCPDS CODE	DESCRIPTION
N/A	

AVAILABLE DOSAGE FORMS:

Koselugo CAPS 10MG

Koselugo CAPS 25MG

Koselugo CPSP 5MG

Koselugo CPSP 7.5MG

REFERENCES

1. Koselugo (selumetinib) capsules, for oral use; oral granules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2025.
2. Gross, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. NEJM. 2020; 382:1430– 1442. doi: 10.1056/NEJMoa1912735
3. Gross AM, Wolters P, Baldwin A, et al. SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) [Abstract]. J Clin Oncol 2018; 36(Suppl15):10503.
4. Dombi, et al. Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas. NEJM. 2016;375:2550–2560. doi: 10.1056/NEJMoa1605943
5. Boyd, et al. Neurofibromatosis Type 1. J Am Acad Dermatol. 2009;61:1–16. doi: 10.1016/j.jaad.2008.12.051
6. National Institutes of Health. In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1. News Release; www.nih.gov. Published March 18, 2020. Accessed April 17, 2020.
7. Masocco, et al. Mortality associated with neurofibromatosis type 1: A study based on Italian death certificates (1995-2006). Orphanet J Rare Dis. 2011;6:11. doi: 10.1186/1750-1172-6-11
8. Jensen SE, Patel ZS, Listernick R, et al. Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood. J Clin Psychol Med Settings 2019; 26:259.
9. National Comprehensive Cancer Network. 2025. Central Nervous System Cancers (Version 3.2024). [online] Available at: < cns.pdf> [Accessed 7 January 2025].
10. National Comprehensive Cancer Network. 2026. Central Nervous System Cancers (Version 3.2025). [online] Available at: < cns.pdf> [Accessed 26 December 2025].

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Quantity FDA-Approved Uses Compendial Approved Off-Labeled Uses Appendix Contraindications/Exclusions/Discontinuation Available Dosage Forms References	Q1 2026
REVISION- Notable revisions: Duration of Approval Quantity Compendial Approved Off- Labeled Uses Appendix Other Special Considerations References	Q1 2025
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Appendix	Q1 2024

Drug and Biologic Coverage Criteria

REVISION- Notable revisions: Required Medical Information Continuation of Therapy Age Restrictions Quantity Appendix Contraindications/Exclusions/Discontinuation Other Special Considerations References	Q1 2023
Q2 2022 Established tracking in new format	Historical changes on file